|1.||Kirchhof, Paulus: 1 article (02/2013)|
|2.||Breithardt, Günter: 1 article (02/2013)|
|3.||Apostolakis, Stavros: 1 article (02/2013)|
|4.||Tebbe, Ulrich: 1 article (02/2013)|
|5.||Fabritz, Larissa: 1 article (02/2013)|
|6.||Oeff, Michael: 1 article (02/2013)|
|7.||Duff, H J: 1 article (12/2006)|
|8.||Somers, J: 1 article (12/2006)|
|9.||Zhan, S: 1 article (12/2006)|
|10.||Sheldon, R S: 1 article (12/2006)|
03/15/1989 - "To determine the efficacy of encainide in the treatment of atrioventricular (AV) node reentrant tachycardia, Holter electrocardiographic (ECG) monitoring, exercise treadmill testing and programmed electrical stimulation were performed in 16 patients while they were taking no medication and after steady state levels were reached during treatment with encainide (75 to 200 mg/day; mean 117 +/- 47). "
10/01/1989 - "No ventricular tachyarrhythmias were induced during programmed ventricular stimulation (baseline study and while receiving encainide therapy). "
10/01/1989 - "At the control study, tachycardia was induced in all patients, with a mean cycle length of 341 +/- 50 ms; after encainide, tachycardia was inducible in only 1 patient, with an increase in cycle length from 270 to 320 ms; in the other patients, tachycardia was not inducible because of a lack of retrograde (11 patients) or anterograde (2 patients) conduction. "
03/01/1993 - "However, in anesthetized dogs studied more chronically after anterior MI (range 8-44 days), i.v. administration of 0.3-3 mg/kg encainide resulted in induction of new ventricular tachyarrhythmias by programmed ventricular stimulation in 6 of 10 dogs with no inducible arrhythmias prior to encainide. "
10/01/1989 - "The electrophysiologic effects of oral encainide (75 to 150 mg daily) were evaluated in 14 patients (6 male and 8 female, aged 49 +/- 9 years) with atrioventricular (AV) node reentrant tachycardia of the slow-fast type. "
09/01/1984 - "Encainide is highly effective in suppressing most nonsustained ventricular arrhythmias, but there is evidence that the drug is less effective and may worsen some arrhythmias, particularly in patients with sustained ventricular tachycardia. "
01/01/1999 - "A young woman is reported with intractable sustained ventricular tachycardia thought to originate in the right ventricle, which was treated successfully with encainide after failure to respond to beta-blockers and several class IA antiarrhythmic agents. "
07/01/1988 - "The short- and long-term efficacy of oral encainide was studied in 14 patients with chronic high-frequency ventricular arrhythmias and in 14 patients with chronic frequent episodes of non-sustained ventricular tachycardia (NSVT). "
10/01/1989 - "Encainide is particularly effective in patients with excessive premature ventricular complexes (PVCs) and less so in patients with sustained ventricular tachycardia (VT). "
04/01/1986 - "At doses of 25 and 50 mg of tid, encainide was effective in suppressing VPCs and in reducing the number of episodes of ventricular tachycardia. "
|3.||Cardiac Arrhythmias (Arrythmia)
09/01/1983 - "Thus, encainide given orally in clinically effective doses does not appear to have significant hemodynamic effects in patients with ventricular arrhythmia and depressed LV function."
01/01/1992 - "Dosage of encainide for patients with lethal ventricular arrhythmias is based on pharmacodynamic effects and efficacy of arrhythmia suppression, coupled with metabolizer phenotype and extent of renal and hepatic dysfunction. "
12/20/1988 - "The safety issues relevant to treatment with encainide in patients with supraventricular arrhythmia were reviewed based on 349 patients enrolled in clinical trials in the United States and Europe. "
08/29/1986 - "Electrophysiology, hemodynamic and arrhythmia efficacy model studies on encainide."
06/01/1982 - "The effects of encainide on ventricular arrhythmia and left ventricular function were studied in 21 patients with chronic, high-grade ventricular arrhythmia using a prospective, 3-month, placebo-controlled, single-blind trial design. "
09/01/1984 - "Based on its electrophysiologic characteristics, encainide, a new type 1 antiarrhythmic agent, was selected for a therapeutic trial in a case of refractory paroxysmal atrial fibrillation. "
08/29/1986 - "Fourteen of 16 patients (88%) with atrial fibrillation continue receiving encainide. "
09/01/1984 - "The use of encainide in atrial fibrillation."
10/01/1989 - "Encainide is also effective for the treatment of supra-ventricular arrhythmias, including atrial fibrillation, PSVT (both PAF as well as reentry of the nodal or W-P-W type), and ectopic atrial tachycardia. "
12/20/1988 - "Encainide is an effective and safe agent for treating atrial fibrillation in patients with Wolff-Parkinson-White syndrome."
12/20/1988 - "Encainide was completely effective in eliminating recurrences of supraventricular tachycardia in 26 of 47 patients (55%) and partially effective in an additional 42%. "
08/29/1986 - "Encainide was effective, or partially effective, in the control of resistant or incessant supraventricular tachycardia in 80% of children treated. "
12/01/1984 - "Encainide proved to be a very useful agent to control incessant supraventricular tachycardia resistant to other antiarrhythmic agents."
12/20/1988 - "Forty-one children (26 weeks gestational age to 20 years) with drug-resistant supraventricular tachycardia were treated with oral encainide, and 29 were followed for 3 to 34 months (mean 15). "
12/20/1988 - "Encainide for resistant supraventricular tachycardia in children: follow-up report."
|5.||Electric Countershock (Cardioversion)